Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients

Diabetes Care. 2005 Jun;28(6):1358-65. doi: 10.2337/diacare.28.6.1358.

Abstract

Objective: Cardiovascular mortality and morbidity are major problems in type 1 diabetic patients with end-stage renal disease (ESRD). The aim of this study was to determine whether islet transplantation can improve cardiovascular function in these patients.

Research design and methods: We assessed various markers of cardiac function at baseline and 3 years later in a population of 42 type 1 diabetic patients with ESRD who received a kidney transplant. Seventeen patients then received an islet transplant that had persistent function as defined by long-term C-peptide secretion (kidney-islet group). Twenty-five patients did not receive a functioning islet transplant (kidney-only group).

Results: GHb levels were similar in the two groups, whereas the exogenous insulin requirement was lower in the kidney-islet group with persistent C-peptide secretion. Overall, cardiovascular parameters improved in the kidney-islet group, but not in the kidney-only group, with an improvement of ejection fraction (from 68.2 +/- 3.5% at baseline to 74.9 +/- 2.1% at 3 years posttransplantation, P < 0.05) and peak filling rate in end-diastolic volume (EDV) per second (from 3.87 +/- 0.25 to 4.20 +/- 0.37 EDV/s, P < 0.05). Time to peak filling rate remained stable in the kidney-islet group but worsened in the kidney-only group (P < 0.05). The kidney-islet group also showed a reduction of both QT dispersion (53.5 +/- 4.9 to 44.6 +/- 2.9 ms, P < 0.05) and corrected QT (QTc) dispersion (67.3 +/- 8.3 to 57.2 +/- 4.6 ms, P < 0.05) with higher erythrocytes Na(+)-K(+)-ATPase activity. In the kidney-islet group only, both atrial natriuretic peptide and brain natriuretic peptide levels decreased during the follow-up, with a stabilization of intima-media thickness.

Conclusions: Our study showed that type 1 diabetic ESRD patients receiving a kidney transplant and a functioning islet transplant showed an improvement of cardiovascular function for up to 3 years of follow-up compared with the kidney-only group, who experienced an early failure of the islet graft or did not receive an islet graft.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atrial Natriuretic Factor / blood
  • C-Peptide / blood
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Physiological Phenomena*
  • Diabetes Mellitus, Type 1 / surgery*
  • Diabetic Nephropathies / surgery*
  • Erythrocytes / enzymology
  • Female
  • Graft Survival
  • Humans
  • Islets of Langerhans Transplantation / physiology*
  • Kidney Transplantation / physiology*
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain / blood
  • Postoperative Complications / epidemiology
  • Sodium-Potassium-Exchanging ATPase / blood

Substances

  • C-Peptide
  • Natriuretic Peptide, Brain
  • Atrial Natriuretic Factor
  • Sodium-Potassium-Exchanging ATPase